Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models

Neurosci Lett. 2021 May 14:753:135844. doi: 10.1016/j.neulet.2021.135844. Epub 2021 Mar 26.

Abstract

The two voltage gated sodium channels Nav1.7 and Nav1.8 are expressed in the peripheral nervous system and involved in various pain conditions including inflammatory and neuropathic pain. Rodent models bearing deletions or mutations of the corresponding genes, Scn9a and Scn10a, were created in order to understand the role of these channels in the pathophysiological mechanism underlying pain symptoms. This review summarizes the pain behavior profiles reported in Scn9a and Scn10a rodent models. The complete loss-of-function or knockout (KO) of Scn9a or Scn10a and the conditional KO (cKO) of Scn9a in specific cell populations were shown to decrease sensitivity to various pain stimuli. The Possum mutant mice bearing a dominant hypermorphic mutation in Scn10a revealed higher sensitivity to noxious stimuli. Several gain-of-function mutations were identified in patients with painful small fiber neuropathy. Future knowledge obtained from preclinical models bearing these mutations will allow understanding how these mutations affect pain. In addition, the review gives perspectives for creating models that better mimic patients' pain symptoms in view to developing novel analgesic strategies.

Keywords: Knockout; Mutant; Nav1.7; Nav1.8; Neuropathic pain; Pain behavior; Rodent model; SCN10A; SCN9A.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Analgesics / pharmacology*
  • Analgesics / therapeutic use
  • Animals
  • Disease Models, Animal
  • Gain of Function Mutation
  • Humans
  • Loss of Function Mutation
  • Mice
  • Mice, Knockout
  • NAV1.7 Voltage-Gated Sodium Channel / genetics*
  • NAV1.7 Voltage-Gated Sodium Channel / metabolism
  • NAV1.8 Voltage-Gated Sodium Channel / genetics*
  • NAV1.8 Voltage-Gated Sodium Channel / metabolism
  • Nociception / drug effects
  • Pain / drug therapy
  • Pain / genetics*
  • Rats
  • Rats, Transgenic
  • Small Fiber Neuropathy / complications*
  • Small Fiber Neuropathy / drug therapy
  • Small Fiber Neuropathy / genetics
  • Voltage-Gated Sodium Channel Agonists / pharmacology
  • Voltage-Gated Sodium Channel Agonists / therapeutic use
  • Voltage-Gated Sodium Channel Blockers / pharmacology
  • Voltage-Gated Sodium Channel Blockers / therapeutic use

Substances

  • Analgesics
  • NAV1.7 Voltage-Gated Sodium Channel
  • NAV1.8 Voltage-Gated Sodium Channel
  • Voltage-Gated Sodium Channel Agonists
  • Voltage-Gated Sodium Channel Blockers